Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFQ056 (mavoglurant) in SSRI-resistant obsessive compulsive disorder
2012-005000-17Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mavoglurant in obsessive compulsive disorder (OCD), sponsored by Novartis. Started Jun 2013; status: terminated.
02
Drugs
mavoglurant
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on 2012-005000-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005000-17.